title: Feasibility and toxicity of concurrent chemoradiation for elderly patients with head and neck cancer.
abstract: OBJECTIVE
  Although concurrent chemoradiation is increasingly used for patients with locally advanced head and neck cancer, many elderly patients receive radiation alone due to toxicity concerns. We evaluate acute and late toxicity among patients age ≥ 65 who received concurrent chemoradiation for head and neck cancer.
  
  
  METHODS
  Retrospective review.
  
  
  METHODS
  Tertiary care center.
  
  
  METHODS
  Between 6/2003 and 8/2011, 40 consecutive patients age ≥ 65 underwent combined chemoradiation for head and neck cancer. Ten patients were treated in the postoperative setting and 30 underwent definitive chemoradiation. Twenty-eight patients received concurrent platinum-based chemotherapy and 12 received concurrent weekly paclitaxel. Treatment plans were designed to provide a dose of 66-72 Gy at 2-2.12 Gy/fraction to >95% of the gross tumor volume in the definitive setting or for positive margins and 60-66 Gy at 2 Gy/fraction post-operatively. Median follow-up was 23.2 months (range: 0-94.4 months).
  
  
  METHODS
  Acute skin and mucosal toxicity, unplanned treatment interruptions, and chronic treatment related toxicity including gastrostomy tube dependence as graded by the CTCAE v3.0.
  
  
  RESULTS
  Eight patients (20%) required a radiation treatment break of ≥ 3 days. Thirteen (33%) required unplanned hospitalization during or immediately following treatment. No grade 4+ skin or mucosal toxicity was noted. Five patients remained PEG tube dependent at >1 year. One patient developed non-healing mandibular osteoradionecrosis >3 years following chemoradiation. The 2-year Kaplan-Meier estimate of overall survival was 55%.
  
  
  CONCLUSIONS
  Higher-than-expected rates of in-patient hospitalization with significant acute toxicity were noted in this cohort with a correspondingly high rate of radiation treatment breaks. Late toxicity rates were similar to those observed in historical controls with younger patients. Careful patient selection criteria should be employed for elderly patients considering concurrent chemoradiation for head and neck cancer.
authors: Department of Radiation Oncology, University of California Davis, Comprehensive Cancer Center, Sacramento, CA, USA. Electronic address: megan.daly@ucdmc.ucdavis.edu.
authors: Megan E
authors: ME
authors: Daly
authors: Derick H
authors: DH
authors: Lau
authors: D Gregory
authors: DG
authors: Farwell
authors: Quang
authors: Q
authors: Luu
authors: Paul J
authors: PJ
authors: Donald
authors: Allen M
authors: AM
authors: Chen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000628:therapy; D000068818:Cetuximab; D059248:Chemoradiotherapy / Q000009:adverse effects*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003872:Dermatitis / Q000145:classification / Q000209:etiology; D004363:Drug Utilization; D016099:Endoscopy, Gastrointestinal / Q000706:statistics & numerical data; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D005774:Gastrostomy / Q000706:statistics & numerical data; D006258:Head and Neck Neoplasms / Q000401:mortality / Q000628:therapy*; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D008336:Mandibular Diseases / Q000209:etiology; D052016:Mucositis / Q000145:classification / Q000209:etiology; D009294:Narcotics / Q000627:therapeutic use; D010025:Osteoradionecrosis / Q000145:classification / Q000209:etiology; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D015431:Weight Loss
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D009294:Narcotics; D016190:Carboplatin; D017239:Paclitaxel; D000068818:Cetuximab; D002945:Cisplatin